Amgen stock: buy or sell?

AMGN stock price: $224.50 1.74% At close on November 19th, 2019

Updated on:
November 19th, 2019


Amgen shares peaked new all time highs again today, setting highs to $224.68. Shares ended at $224.50 and jumped 1.74%.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology\u002Fhematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.

Should I buy Amgen stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

These 2 buy setups are elegible for Amgen stock now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Amgen stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At, we detected 15 ratings published for AMGN stock in the last month.

Is AMGN a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-5Cantor Fitzgeraldn/aNeutral
2019-8-30William Blairn/aHold
2019-8-29JPMorgan Chase & Co.n/aNeutral
2019-8-27Wells Fargo & Con/aMarket Perform
2019-8-27Royal Bank of Canadan/aSector Perform
2019-8-27JPMorgan Chase & Co.n/aHold
2019-8-27BMO Capital Marketsn/aOutperform
2019-8-21Royal Bank of Canadan/aSector Perform
2019-8-16Credit Suisse Groupn/aOutperform
2019-8-12Wells Fargo & CoMarket PerformPositive
2019-7-15Morgan Stanleyn/aOverweight

Amgen stock analysis

Daily outlook

After climbing to all-time highs several times in past weeks, Amgen jumped 1.74% to $224.50.

Amgen closed today at $224.50 after topping to a new all time high ($224.68) and jumped a fine 1.74%. Since SMA100d and SMA200d crossed up on October, AMGN price climbed $32.27 per share (16.79%). On August AMGN price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. AMGN shows a strong short term uptrend with several rising tops and rising bottoms. Since its last bottom on Thursday, AMGN climbed unceasignly breaking out to new all time highs.

AMGN stock chart (daily)

Weekly outlook

Amgen stepped up 1.65% this week and peaked a new all time high at $224.68. With this, it's been 5 climbing weeks in a row, soaring a 11.59%. Late October AMGN rocketed an amazing 6.84% in just one week.

AMGN shows a strong mid-term uptrend with several rising tops and rising bottoms. Since its last bottom late September, AMGN climbed unceasignly breaking out to new all time highs. Since SMA20d and SMA40w crossed up late September, AMGN price climbed $28.86 per share (14.75%). Late July AMGN price bounced up over the SMA of 40 weeks that acted as support stopping new slides.

AMGN stock chart (weekly)

Amgen stock price history

Amgen stock went public on June 17th, 1983 with a price of $0.001. Since then, AMGN stock grew a inf%, with an average of inf% per year. If you had invested $1,000 in Amgen stock in 1983, it would worth $inf today.

1: Adjusted price after possible price splits or reverse-splits.

Amgen stock historical price chart

AMGN stock reached all-time highs today with a price of $224.68.

Amgen stock price target is $214.00

How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We found 13 price forecasts for Amgen stock posted in the last 30 days:
AMGN stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-5Cantor FitzgeraldReiterates$221.00$230.004.1%
2019-8-29JPMorgan Chase & Co.Raises Target$191.00$198.003.7%
2019-8-27Wells Fargo & CoReiterates$202.00$220.008.9%
2019-8-27Royal Bank of CanadaRaises Target$192.00$206.007.3%
2019-8-27BMO Capital MarketsRaises Target$230.00$240.004.3%
2019-8-21Royal Bank of CanadaRaises Targetn/a$192.00-
2019-8-16Credit Suisse GroupReiterates$202.00$225.0011.4%
2019-8-13OppenheimerRaises Target$210.00$230.009.5%
2019-8-12Wells Fargo & CoReiterates$197.00$202.002.5%
2019-7-15Morgan StanleyLowers Target$211.00$207.00-1.9%
(in average)$206.40$214.004.0%
The price prediction for Amgen stock is $214.00, moving in a range between $240.00 and $192.00. In average, analysts' outlook on AMGN price target is positive, increasing the forecast by a 4.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Since last April, when Amgen posted its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
AMGN earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Amgen annual revenues inched a good 3.93% to $23,747.00 M USD from $22,849.00 marked in 2017. When comparing 2018 vs 2017, slightly better, profit margin (that is, the net income divided by revenues) skyrocketed a 26.69% to 35.35%.

To have an updated view of the financial situation of Amgen, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Amgen TTM sales up to March 2019 were $23,750.00 and earnings were $8,075.00 million USD. When comparing this TTM figures with the last reported annuality, we can review Amgen business evolution since December 2018: Annual sales up to March, compared to lastest yearly report, remained stable a tight 0.01%. Similarly, profit margin (net income/sales) depreciated at 35.35%.

AMGN annual Sales and Income evolution
2013$18,670 M-$5,080 M27.2%-
2014$20,063 M7.46%$5,158 M25.7%1.54%
2015$21,662 M7.97%$6,939 M32.0%34.53%
2016$22,991 M6.14%$7,722 M33.6%11.28%
2017$22,849 M-0.62%$1,979 M8.7%-74.37%
2018$23,747 M3.93%$8,394 M35.3%324.15%
TTM $23,750 M0.01%$8,075 M34.0%-3.80%

Quarterly financial results

Amgen posted $5,557.00 million in sales for 2019-Q1, a -10.80% less compared to previous quarter. Reported quarter earnings marked $1,992.00 million with a profit margin of 35.85%. Profit margin raised a 4.90% compared to previous quarter when profit margin was 30.95%. When comparing turnover to same quarter last year, Amgen sales marked a neutral movement and stayed steady a 0.05%.
AMGN quarterly Sales and Income evolution
2017-Q2$5,780 M-$2,150 M37.2%-
2017-Q3$5,780 M0.00%$2,020 M34.9%-6.05%
2017-Q4$5,802 M0.38%$-4,264 M-73.5%-311.09%
2018-Q1$5,554 M-4.27%$2,311 M41.6%-154.20%
2018-Q2$6,059 M9.09%$2,296 M37.9%-0.65%
2018-Q3$5,904 M-2.56%$1,859 M31.5%-19.03%
2018-Q4$6,230 M5.52%$1,928 M30.9%3.71%
2019-Q1$5,557 M-10.80%$1,992 M35.8%3.32%

Amgen ownership

When you are planning to invest in shares of a company, it's worth to review its ownership structure.

Amgen shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.21% of all shares.

Bearish positions for AMGN stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Amgen:

Market cap$133.4 B$131.3 B$24.2 B$51.0 B$94.0 B
Total shares594.2 M1,480.0 M224.2 M180.4 M1,630.0 M
Float shares592.9 M1,480.0 M220.7 M180.0 M1,630.0 M
  - Institutional holdings (%)81.9%71.9%96.8%93.4%75.0%
  - Insider holdings (%)0.2%0.1%0.3%0.5%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Amgen summary

Tuesday, November 19th, 2019
Day range$220.70 - $224.68
Previous close$220.67
Session gain1.74%
Average true range$4.18
50d mov avg$203.16
100d mov avg$196.02
200d mov avg$187.34
Daily patternlb03c
Weekly pattern lb03c

Amgen performance

To better understand Amgen performance you must compare its gains with other related stocks in same sector or industry. We picked AbbVie, Alexion Pharmaceuticals, Biogen, Bristol-Myers Squibb, Celgene, Gilead Sciences, GlaxoSmithKline, and Pfizer as the bechmarking frame for Amgen stock.
ALXNAlexion Pharmaceu...-6.38%-15.01%-8.58%
BMYBristol-Myers Squ...24.81%25.30%12.66%
GILDGilead Sciences3.81%-2.07%0.17%

Amgen competitors

One check before investing in any stock is to have a look a list of its competitors, in this case for Amgen. We chose 9 companies as Amgen competitors as they are in the same industry or have similar market objectives.

Latest Amgen stock news